The most common cardiac arrhythmia worldwide, atrial fibrillation (AF) is a leading cause of stroke, heart failure, cardiovascular morbidity, and sudden death. The global prevalence and incidence of AF are increasing steadily, particularly in developed countries, and associated increases in morbidity and mortality have been noted.
Diagnosis of AF is challenging because brief or intermittent episodes can be easy to miss, and the condition may produce mild symptoms that patients do not associate with heart problems. Oral anticoagulation therapy reduces the risk of ischemic stroke by up to 70% in patients with AF, but undertreatment, driven in part by underdiagnosis, remains a major impediment to optimal care.
To improve the ability of clinicians to identify and appropriately address nonvalvular atrial fibrillation (NVAF), the Heart Rhythm Society (HRS) and Haymarket Medical Education (HME) have developed this innovative and collaborative educational initiative. The curriculum uses a mix of live, mobile, and online educational modalities to address key professional practice gaps in care, focusing on the importance of identifying and screening patients for NVAF, and on subsequent appropriate treatment strategies, in an effort to reduce the risk of stroke.
Atrial fibrillation—or AFib—is the most common type of irregular heartbeat and can lead to some serious complications, including stroke. Could you be at risk? Find out here. Use the other resources on this page from the Heart Rhythm Society to learn more about Afib, and talk to your doctor about how you can minimize your risk for stroke and related complications.
James Daubert, MD
Professor of Medicine
Chief, Cardiac Electrophysiology
Duke University Medical Center
Paul Doghramji, MD, FAAFP
Collegeville Family Practice
Medical Director, Health Services
Kelly M. Rudd, PharmD, FCCP, BCPS, CACP
Director, Network Pharmacy
Bassett Healthcare Network
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
UC Irvine Department of Family
Associate Dean for Diversity and
UC Irvine School of Medicine
Supported by an
educational grant from the
Bristol-Myers Squibb and Pfizer Alliance
Disclosure Policy and Resolution of Conflicts of Interest Statement
In accordance with the ACCME Standards for Commercial Support, HRS requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HRS resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Furthermore, HRS seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. HRS is committed to providing its learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they have with commercial interests related to the content of this CME activity:
James Daubert, MD, has received honoraria and/or consulting fees from the American College of Cardiology (as Associate Editor for JACC-EP); ARCA Biopharma; Biotronik; Boston Scientific; Medtronic; St. Jude; VytronUS, Inc.; LivaNova PLC; and Zoll Medical Corporation. He has received research grants and/or fellowship funds from ARCA Biopharma; Biosense Webster, Inc.; Boston Scientific; Gilead Sciences, Inc.; Medtronic; NIH/NHLBI; and St. Jude and is on the advisory boards of Biosense Webster, Inc.; Gilead Sciences, Inc.; Iowa Approach, LLC; and Medtronic.
Paul Doghramji, MD, FAAFP, has been on the advisory boards of and has received honoraria and/or consulting fees from Alkermes, Harmony Pharmaceuticals, and Jazz Pharmaceuticals and has stock and/or stock options in Pfizer Inc.
Kelly M. Rudd, PharmD, FCCP, BCPS, CACP, has no relevant financial relationships to disclose.
Charles Vega, MD, FAAFP, has received honoraria and/or consulting fees from and is a speaker and/or consultant for Johnson & Johnson and Shire Pharmaceuticals.
HRS’s physician content reviewers have no relevant financial relationships to disclose.
Accredited Provider Disclosures
The staff of HRS and Haymarket Medical Education (HME) involved in the planning and content review of this activity have no relevant financial relationships to disclose.